Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 19, 2006

View Archived Issues

Preclinical and clinical antithrombotic efficacy of rivaroxaban reported

Sequencing of human breast and colorectal cancers provides novel targets for drug design

AMD-3100 and G-CSF mobilize angiogenic cells, show wide clinical application

NovaDel Pharma adds oral spray drug development candidates to pipeline

Juvaris awarded SBIR grant for biodefense work

Anthera secures funding for novel secretory phospholipase programs

GSK reports on another successful quarter

Stem Cell Therapeutics options EPO programs in schizophrenia and MS

Phase IIa study of microplasmin in vitrectomy completes treatment

NuCana signs agreement with Cardiff ProTides to develop novel cancer agents

Bill & Melinda Gates Foundation supports efforts in hookworm and leishmaniasis

NV-1020 shows efficacy in liver metastases study

SQ-109 to begin clinical testing for tuberculosis

AstraZeneca and Schering to codevelop novel SERD for breast cancer

Phase II trial evaluates MGCD-0103 in relapsed or refractory B-cell lymphomas

Amgen presents novel TRPV1 antagonists with antinociceptive efficacy

SCV-07 shows oral bioavailability

Results for CTI-01 in cardiac surgery patients

Ginkgo biloba extract effective against postsurgical hypersensitivity

Efficacy of aliskiren/ramipril combination shown in hypertensive diabetic patients

Safety of ruboxistaurin in diabetic complications: results from 11 phase II and III trials

Antidiabetic efficacy of the DPP-IV inhibitor MP-513 shown in Zucker fatty rats

FDA approves first antifungal agent for prevention of IFIs caused by Aspergillus

Amgen reveals novel ACK1 inhibitors as anticancer candidates

Glivec approved in E.U. for additional cancer indications

Lyrica indications broadened in E.U. to include central neuropathic pain

Protherics seeks approval in U.S. for Voraxaze

Novel agents claimed for use in arthritis and other inflammatory disorders

Antipsoriatic agents prepared and tested at Relivia

New therapeutic agents for respiratory disorders revealed

Pfizer reports on promising anticancer development of new RTK inhibitor

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
Gene replacement rescues autism-related phenotypes in mice
BioWorld Science
Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...